Tirzepatide, a dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β‐cells and hepatic steatosis in obese type 2 diabetic db/db mice

Documenti analoghi

• The impact of grip strength, waist circumference, and body mass index on Hemoglobin A1c value: Cross‐sectional study using outpatient clinical data in Japanese elderly patients with type 2 diabetes mellitus
  di: Shuhei Nakanishi, et al.
  Pubblicazione: (2024)
• The impact of handgrip strength and waist circumference on glycemic control: Prospective, observational study using outpatient clinical data in Japanese patients with type 2 diabetes mellitus
  di: Shuhei Nakanishi, et al.
  Pubblicazione: (2024)
• Usefulness of Once‐Weekly GLP‐1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study
  di: Tomohiko Kimura, et al.
  Pubblicazione: (2024)
• Efficacy and safety of imeglimin add‐on to DPP ‐4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double‐blind FAMILIAR trial
  di: Kohei Kaku, et al.
  Pubblicazione: (2025)
• Effect of Weight‐Neutral Treatment With Semaglutide or Tirzepatide on β‐Cell Identity in db / db Mice
  di: Zhaobin Deng, et al.
  Pubblicazione: (2025)